Market Place
Sourcing Support
IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6
23 Jan 2024 //
BUSINESSWIRE
IAMA Announces Approval of CTA by AIFA to Initiate a Phase 1 Study of IAMA-6
20 Dec 2023 //
BUSINESSWIRE
IAMA to Present Data at American Epilepsy Society 2023 Annual Meeting
01 Dec 2023 //
BUSINESSWIRE
IAMA Announces Multi-Phase, Strategic Provider Agreement with Evotec
02 Oct 2023 //
BUSINESSWIRE
IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe
13 Sep 2023 //
BUSINESSWIRE
IAMA Therapeutics Announces Agreement with The Sapienza University of Rome
10 Jul 2023 //
BUSINESSWIRE
IAMA Therapeutics to Present at Upcoming BIO International Convention
01 Jun 2023 //
BUSINESSWIRE
IAMA Announces Addition of Paul Frohna, Pierandrea Muglia and Elaine Wirrell to Scientific Advisory Board
31 May 2023 //
BUSINESSWIRE
PsychoGenics on board for Iama`s Dravet syndrome study
19 Jan 2023 //
FIERCE BIOTECH
IAMA and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
12 Jan 2023 //
BUSINESSWIRE
IAMA Tx Initiates Preclinical Development Studies in Drug-resistant Epilepsy
25 Jul 2022 //
BUSINESSWIRE
IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors
29 Jun 2022 //
BUSINESSWIRE
IAMA Tx Announces Oral Presentation at the XXVII EFMC International Symposium
24 May 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.